Dorra Pharma is proud to announce that its self-developed core active pharmaceutical ingredient (API), Fosfomycin Trometamol, has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP) (Certificate……
From June 24 to 26, the 23rd edition of CPHI China was successfully held in Shanghai. As a global leader in innovation-driven API partnerships, Dorra leveraged this premier platform to comprehensively showcase its streng……
From April 9 to 22, the 2025 CPHI Japan was grandly held in Tokyo. Led by Chairman Mr. Shengjun Zhao, Dorra and its European office participated in the exhibition, showcasing the company’s innovative achievements and glo……
From October 8th to 20th, the three-day global premier pharmaceutical event—CPhI Worldwide 2024—successfully concluded in Milan, Italy. The event attracted over 62,000 participants from more than 266 countries and region……
We are excited to announce that on July 2st, Dorra Pharmaceuticals officially established its first overseas office in Europe. This strategic move marks a significant milestone in our journey towards international growth……
From June 29 to 22, the 22nd CPHI China 2024 was successfully held at the Shanghai New International Expo Centre. This prestigious event gathered over 3,500 leading companies from the global pharmaceutical industry and a……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
